Cargando…
Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor
(1) Background: Two first-in-class racemic dopamine D(1) receptor (D(1)R) positive allosteric modulator (PAM) chemotypes (1 and 2) were identified from a high-throughput screen. In particular, due to its selectivity for the D(1)R and reported lack of intrinsic activity, compound 2 shows promise as a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270344/ https://www.ncbi.nlm.nih.gov/pubmed/34206465 http://dx.doi.org/10.3390/molecules26133799 |
_version_ | 1783720785101193216 |
---|---|
author | Fyfe, Tim J. Scammells, Peter J. Lane, J. Robert Capuano, Ben |
author_facet | Fyfe, Tim J. Scammells, Peter J. Lane, J. Robert Capuano, Ben |
author_sort | Fyfe, Tim J. |
collection | PubMed |
description | (1) Background: Two first-in-class racemic dopamine D(1) receptor (D(1)R) positive allosteric modulator (PAM) chemotypes (1 and 2) were identified from a high-throughput screen. In particular, due to its selectivity for the D(1)R and reported lack of intrinsic activity, compound 2 shows promise as a starting point toward the development of small molecule allosteric modulators to ameliorate the cognitive deficits associated with some neuropsychiatric disease states; (2) Methods: Herein, we describe the enantioenrichment of optical isomers of 2 using chiral auxiliaries derived from (R)- and (S)-3-hydroxy-4,4-dimethyldihydrofuran-2(3H)-one (d- and l-pantolactone, respectively); (3) Results: We confirm both the racemate and enantiomers of 2 are active and selective for the D(1)R, but that the respective stereoisomers show a significant difference in their affinity and magnitude of positive allosteric cooperativity with dopamine; (4) Conclusions: These data warrant further investigation of asymmetric syntheses of optically pure analogues of 2 for the development of D(1)R PAMs with superior allosteric properties. |
format | Online Article Text |
id | pubmed-8270344 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82703442021-07-10 Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor Fyfe, Tim J. Scammells, Peter J. Lane, J. Robert Capuano, Ben Molecules Article (1) Background: Two first-in-class racemic dopamine D(1) receptor (D(1)R) positive allosteric modulator (PAM) chemotypes (1 and 2) were identified from a high-throughput screen. In particular, due to its selectivity for the D(1)R and reported lack of intrinsic activity, compound 2 shows promise as a starting point toward the development of small molecule allosteric modulators to ameliorate the cognitive deficits associated with some neuropsychiatric disease states; (2) Methods: Herein, we describe the enantioenrichment of optical isomers of 2 using chiral auxiliaries derived from (R)- and (S)-3-hydroxy-4,4-dimethyldihydrofuran-2(3H)-one (d- and l-pantolactone, respectively); (3) Results: We confirm both the racemate and enantiomers of 2 are active and selective for the D(1)R, but that the respective stereoisomers show a significant difference in their affinity and magnitude of positive allosteric cooperativity with dopamine; (4) Conclusions: These data warrant further investigation of asymmetric syntheses of optically pure analogues of 2 for the development of D(1)R PAMs with superior allosteric properties. MDPI 2021-06-22 /pmc/articles/PMC8270344/ /pubmed/34206465 http://dx.doi.org/10.3390/molecules26133799 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fyfe, Tim J. Scammells, Peter J. Lane, J. Robert Capuano, Ben Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor |
title | Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor |
title_full | Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor |
title_fullStr | Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor |
title_full_unstemmed | Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor |
title_short | Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor |
title_sort | enantioenriched positive allosteric modulators display distinct pharmacology at the dopamine d(1) receptor |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270344/ https://www.ncbi.nlm.nih.gov/pubmed/34206465 http://dx.doi.org/10.3390/molecules26133799 |
work_keys_str_mv | AT fyfetimj enantioenrichedpositiveallostericmodulatorsdisplaydistinctpharmacologyatthedopamined1receptor AT scammellspeterj enantioenrichedpositiveallostericmodulatorsdisplaydistinctpharmacologyatthedopamined1receptor AT lanejrobert enantioenrichedpositiveallostericmodulatorsdisplaydistinctpharmacologyatthedopamined1receptor AT capuanoben enantioenrichedpositiveallostericmodulatorsdisplaydistinctpharmacologyatthedopamined1receptor |